What’s the current market cap for Minimed Group stock?

Minimed Group (MMED) has a market cap of $4.3bn as of June 12, 2026.

What is the P/E ratio for Minimed Group stock?

The price to earnings (P/E) ratio for Minimed Group (MMED) stock is 0 as of June 12, 2026.

Does Minimed Group stock pay dividends?

No, Minimed Group (MMED) stock does not pay dividends to its shareholders as of June 12, 2026.

When is the next Minimed Group dividend payment date?

Minimed Group (MMED) stock does not pay dividends to its shareholders.

What is the beta indicator for Minimed Group?

Minimed Group (MMED) does not currently have a Beta indicator.

Buy Minimed Group stock | $MMED Share Price

13:30

15:10

16:45

18:25

20:00

About Minimed Group

Minimed Group Inc is a medical technology firm that develops, manufactures, and markets products and solutions for diabetes management. It offers automated insulin pumps, continuous glucose monitoring systems and sensors, and smart insulin pens as its main products. The company sells these through direct-to-consumer channels and healthcare providers of various countries. The company's revenues are principally derived from the sale of reusable and single-use products which together comprise AID systems and smart multiple daily injection (MDI) systems for diabetes management to individuals, distributors, healthcare providers, and other institutions globally.

Ticker

$MMED

Sector

Health

Primary listing

NASDAQ

Employees

8,000

Headquarters

Northridge, United States

Website

www.minimed.com

Minimed Group Metrics

BasicAdvanced

$4.3bn

-$1.29

What the Analysts think about Minimed Group

Analyst ratings (Buy, Hold, Sell) for Minimed Group stock.

Bulls say / Bears say

MMED grew revenue 15% to $1.5 billion year-over-year in H1 FY2025 while narrowing its net loss from $23 million to $21 million, demonstrating improving operating leverage (Bloomberg)

The $560 million raised in MMED’s March 6 IPO provides substantial capital for R&D, marketing expansion, and working capital as a standalone entity (Bloomberg)

Under CEO Que Dallara’s leadership, MMED is positioning its insulin pumps and continuous glucose monitors as an integrated “self-driving” diabetes management system, potentially creating a high-value competitive moat (Bloomberg)

Shares slid 8% on their trading debut, closing at $18.49 versus the $20 IPO price, signaling tepid investor demand (Bloomberg)

Analysts question whether MMED’s growth prospects justify its post-IPO valuation of roughly $5.2 billion, highlighting concerns over stretched multiples for a standalone diabetes-device unit (Bloomberg)

Despite revenue growth to $1.5 billion in H1 FY2025, MMED remains unprofitable with a net loss of $21 million, underscoring ongoing challenges on the path to operating profitability (Bloomberg)

Data summarised monthly by Lightyear AI. Last updated on 10 Jun 2026.

Minimed Group Financial Performance

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37bn

-39.75%

Net income

$45bn

107.52%

Profit margin

37.65%

6.78%

Minimed Group Earnings Performance

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $MMED

Capital at risk

Market open

Upcoming events

No upcoming events